Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common ...
March 21 2017 - 3:10PM
WALTHAM, Mass., March 21, 2017 (GLOBE NEWSWIRE) --
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of innovative
therapies to treat unmet medical needs of central nervous system
(CNS) disorders, today announced the recent exercise of warrants
held by certain institutional stockholders in connection with a
private placement that took place in March 2015, as well as a
purchase of common stock completed on the open market by the
chairman of Minerva's board of directors.
Since December 31, 2016, warrants with respect to
a total of 1,621,073 shares have been exercised by such
stockholders at an exercise price of $5.772 per share. As a
result, the Company has received approximately $9.4 million in
proceeds since December 31, 2016. The warrants issued in connection
with the private placement expired on March 20, 2017.
Separately, 50,000 shares of Minerva common stock
have been purchased by Marc Beer, chairman of the board of
directors of Minerva. These purchases took place in multiple
transactions at prices ranging from $7.65 to $8.45 and have been
reflected in a Form 4 filing with the Securities and Exchange
Commission on March 21, 2017.
About Minerva
Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of product candidates to treat CNS
diseases. Minerva's proprietary compounds include: MIN-101,
in clinical development for schizophrenia; MIN-117, in clinical
development for major depressive disorder (MDD); MIN-202
(JNJ-42847922), in clinical development for insomnia and MDD; and
MIN-301, in pre-clinical development for Parkinson's disease.
Minerva's common stock is listed on the NASDAQ Global Market under
the symbol "NERV." For more information, please
visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024